[Metoclopramide, methylprednisolone and flunitrazepam in cytostatic-induced vomiting].
The antiemetic efficacy of a combination of high-dose metoclopramide, methylprednisolone and flunitrazepam was tested in an open pilot study in 30 tumor patients undergoing strongly emetic chemotherapy. 26 of 30 patients (87%) were partially or completely protected from nausea and vomiting. In 11 of 12 patients receiving the strongly emetogenic cytostatic agent cisplatin in a dose of greater than or equal to 50 mg/m2, the gastrointestinal side effects were partially or completely abolished. The antiemetic efficacy of the combination was maintained during subsequent courses of chemotherapy. All patients experienced somnolence after administration of flunitrazepam. Only 2 of 30 patients had a shortlived extrapyramidal reaction. The combination of high-dose metoclopramide, methylprednisolone and flunitrazepam is an effective antiemetic treatment and should be considered as first-line antiemetic treatment in patients receiving strongly emetic cancer chemotherapy.
Institut für Medizinische Onkologie der Universität, Bern.
R
R
Joss
D
D
Rohrbach
M
M
Pirovino
A
A
Bischoff
J
J
Kiser
K
K
Brunner
D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D005445:Flunitrazepam / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D005445:Flunitrazepam; D008787:Metoclopramide; D008775:Methylprednisolone
Metoclopramid, Methylprednisolon und Flunitrazepam beim zytostatika-bedingten Erbrechen.